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ABSTRACT
Liver injury is a great threat associated with anti-tuberculosis (anti-TB) medication. Genetic variations in genes 
encoding drug-metabolising enzymes further enhance this threat. We aimed to explore genetic contributions by 
evaluating the impact of single nucleotide polymorphisms (SNPs) within the anti-tuberculosis (AT) metabolism pathway 
genes and within their respective chromosomes on anti-tuberculosis drug- induced liver injury (AT-DILI). Patients (n= 
90) were recruited and 170 SNPs were genotyped using Illumina array and validated using Sanger Sequencing. The 
well-studied N-acetyltransferase 2 (NAT2*6) rs1799930 and cytochrome P450 2E1 (CYP2E1) C1/C1 were not 
significantly associated with AT-DILI in our cohort but nitric oxide synthase (NOS2A) rs11080344-C was found to be 
significantly higher in the cases than the controls (OR 2.73, 95% CI 1.12-6.64, P= 0.027). Association studies on all 
other SNPs within the anti-tuberculosis metabolism pathway genes and within their respective chromosomes also found 
no significant report. Our study suggests that genetic variation in NOS2A could influence the occurrence of AT-DILI.
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ABSTRAK
Kerosakan hati adalah ancaman besar yang dikaitkan dengan pengambilan ubat-ubatan anti-tuberkulosis. Variasi 
genetik dalam gen yang mengekod enzim yang terlibat dalam metabolisme ubat meningkatkan ancaman tersebut. 
Tujuan kami adalah untuk mengkaji pengaruh genetik dengan menilai impak polimorfisme nukleotid tunggal (SNPs) di 
dalam gen-gen yang terlibat dalam laluan metabolisme ubat-ubatan anti-tb dan dalam kromosom masing-masing 
terhadap kecenderungan kerosakan hati akibat ubat anti-tuberkulosis (AT-DILI). Pesakit (n=90) direkrut dan 170 SNPs 
digenotip menggunakan tatasusunan Illumina dan disahkan menggunakan penjujukan Sanger. Gen N-asetiltransferase 
2 (NAT2*6) rs1799930 dan sitokrom P450 2E1 (CYP2E1) C1/C1 yang dikaji secara meluas tidak mempunyai kaitan 
signifikan dengan AT-DILI dalam kohort kami tetapi nitrik oksida sintase (NOS2A) rs11080344-C didapati secara 
signifikannya lebih tinggi dalam subjek kes berbanding dengan subjek kawalan (OR 2.73, 95% CI 1.12-6.64, P= 0.027). 
Kajian SNPs lain yang terlibat di dalam gen dalam laluan matabolisme ubat-ubatan anti-tuberkulosis dan kromosom 
masing-masing juga tidak menunjukkan kaitan yang signifikan. Kajian kami mencadangkan bahawa variasi genetik di 
dalam NOS2A boleh mempengaruhi kejadian AT-DILI.
Kata kunci: Kerosakan hati; kesan buruk; nitrik oksida; tuberkulosis; variasi genetik
INTRODUCTION
Pharmaceutical drugs on the whole greatly improve patient 
outcomes and quality of life. Although used as prescribed, 
they are not without their complications. Anti-tuberculosis 
medication which is used in the treatment of Mycobacterium 
tuberculosis is also seen to cause various adverse effects 
to the human body which can lead to delay in treatment 
outcome, drug resistance, treatment failure, and a 
corresponding increase in disease morbidity and mortality 
(Farazi et al. 2014). Anti-tuberculosis drug- induced liver 
injury (AT-DILI) is the most common and serious adverse 
effect associated with anti-tuberculosis medication 
(Tostmann et al. 2008). The first-line tuberculosis drugs 
recommended by World Health Organization (WHO) 
include isoniazid (INH), rifampicin and pyrazinamide 
which are potentially hepatotoxic (World Health 
Organization 2010) and are used together with ethambutol. 
Isoniazid is principally associated with AT-DILI with many 
reports addressed liver injury when used in combination 
with isoniazid (Farrell 1994; Kurniawati et al. 2012; 
Thongraung et al. 2012; Tostmann et al. 2008; Xue et al. 
2002).
Genetic risk factors of AT-DILI include genes that are 
involved in the metabolism of the anti- tuberculosis (anti-
TB) drugs. Isoniazid is first metabolised to acetylisoniazid 
via N-acetyltransferase 2 (NAT2), followed by hydrolysis 
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to acetylhydrazine (Huang 2014). Cytochrome P450 2E1 
(CYP2E1) subsequently oxidizes acetylhydrazine to a 
hepatotoxic intermediate, some of which can be detoxified 
by the glutathione S-transferase (GST) enzyme (Huang 
2014). Another metabolic pathway that generates toxic 
intermediates is the direct hydrolysis of INH to hydrazine, 
a potent hepatotoxin (Huang 2014). A meta-analysis 
showed that the genotypes NAT2 mt/mt, CYP2E1*1A/*1A 
and glutathione S-transferase enzyme M1 (GSTM1) null/
null are associated with increased risk of AT-DILI (Sun et 
al. 2008) and these associations are significantly evidenced 
in the East Asian population (Huang 2014). A Brazilian 
study later demonstrated that slow acetylation status (NAT2 
variant) is the only independent risk factor for AT-DILI 
involving isoniazid (Teixeira et al. 2011).
Malaysia shares many aspects of the global challenges 
of tuberculosis (TB)-related health problems, especially in 
recent years in view of the rising incidence of human 
immunodeficiency virus (HIV)/TB co-infection and influx 
of foreign workers from neighbouring countries with high 
tuberculosis related cases (Ministry of Health Malaysia 
2015; Rafiza et al. 2011). Statistics on the incidence of 
AT-DILI in the Malaysian population is scarce. A 
retrospective study that was carried out showed the 
incidence of AT-DILI as recorded by the Hospital Universiti 
Sains Malaysia, Kelantan, is 9.7% (Marzuki et al. 2008). 
Apart from NAT2, the bulk of research on AT-DILI to date 
presents conflicting results and there are marked differences 
in pharmacogenetics between various populations. In this 
study, we investigated the association of SNPs in the anti-
tuberculosis drug metabolism pathway genes (Huang 2014) 
which include NAT2, CYP2E1, superoxide dismutase 2 
(SOD2), BTB domain and CNC homolog 1 (BACH1), and 
nitric oxide synthase (NOS2A) with risk of liver injury in 
the Malaysian population. 
MATERIALS AND METHODS
ETHICS APPROVAL
This study was approved by the medical ethics committees 
for clinical research from the University of Malaya Medical 
Centre (UMMC) (reference number: 955.11) and the 
National Medical Research Register (NMRR) (NMMR-13-
443-15579). A written informed consent was obtained from 
each subject prior to participation in the study.
SUBJECT RECRUITMENT
Subjects were recruited from the UMMC and the Institute 
of Respiratory Medicine (IRM) located in Kuala Lumpur, 
Malaysia. Both institutions are tertiary referral medical 
centres which receive patients from most parts of Malaysia 
irrespective of ethnicity and social backgrounds. Patients 
were recruited in the TB treatment clinic which is referred 
to as Directly Observed Treatment Strategy (DOTS) clinic, 
in the respective hospitals based on the following criteria; 
diagnosis of TB, taking the first-line anti-TB regimen 
(isoniazid, rifampicin, pyrazinamide and ethambutol), 
willing to participate in the study as well as able to give 
informed consent (signed by patient or surrogate). Patients 
below 18 years age, have other diseases or terminal 
illnesses, unwilling to participate in the study or unable to 
give consent, have abnormal liver function (before starting 
anti-TB medication), and also patients with HIV and 
hepatitis B and hepatitis C patients were excluded from 
this study. Once a potential participant was identified 
during their first visit to the DOTS, an appointment was 
arranged 4-8 weeks after the initiation of anti-TB treatment 
for review and liver function monitoring. During the follow 
up, participants were assessed for symptoms and signs 
suggestive of drug-induced liver injury (DILI) and blood 
was collected for liver function test and pharmacogenetics 
study.
AT-DILI CRITERIA
AT-DILI assessment was based on the hepatotoxicity that 
was developed as stated by the American Thoracic 
Society (Saukkonen et al. 2006) and adapted from Shang 
et al. (2011). AT-DILI was specifically diagnosed when 
there is an increase in serum aspartate aminotransferase 
(AST) or serum alanine aminotransferase (ALT) that is 
greater than three times of the upper limit normal (ULN) 
or an increase in total bilirubin that is greater than two 
times of the ULN, in the absence of viral hepatitis 
infections, also excluding the use of potentially 
hepatotoxic drugs, current or previous alcohol 
consumption >10 g/day and other active liver diseases 
(Saukkonen et al. 2006; Shang et al. 2011; Ruhl & 
Everhart 2005). Tuberculosis patients administered with 
the standard anti-tuberculosis regimen and did not satisfy 
the criteria for cases as reviewed by the clinician were 
categorised as controls. 
SELECTION OF SINGLE                                            
NUCLEOTIDE POLYMORPHISMS (SNPs)
A total of 170 SNPs within chromosomes harbouring the 
anti-tuberculosis drug metabolism pathway genes (Huang 
2014), particularly the N-acetyltransferase 2 (NAT2), 
cytochrome P450 2E1 (CYP2E1), superoxide dismutase 2 
(SOD2), BTB domain and CNC homolog 1 (BACH1), and 
nitric oxide synthase (NOS2A), were selected and designed 
for the Illumina genotyping array. 
DATA COLLECTION
Demographic data collected included race, age, gender, 
and weight. Information on type of TB, smear type, date 
of treatment initiation, history of TB-related adverse drug 
reaction, alcohol history, and hepatitis B and C status were 
recorded. Patients’ baseline (before the start of medication) 
liver function test (LFT) was reviewed from their medical 
record. LFT results 4-8 weeks after initiation of medication 
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was obtained from the respective diagnostic centre of the 
two hospitals.
DNA ISOLATION
Blood was separated to red blood cells, buffy coat and 
plasma via centrifugation. DNA extraction was conducted 
on the buffy coat using QIAmp DNA Mini kit (QIAGEN, 
USA). A total volume of 150 µl DNA was obtained from 
the extraction and qualitative as well as quantitative 
est imations were performed using NanoDrop 
spectrophotometer (Thermo Scientific). Approximately 50 
ng of DNA sample was utilised in the genotyping.
GENOTYPING
Genotyping was done using Illumina HumanOmniExpress-24 
beadchip (Illumina, San Diego, CA) in collaboration with 
Translational Laboratory in Genetic Medicine, A*STAR, 
Singapore and Genome Institute of Singapore using a total 
of 90 samples. QC was performed to remove samples with 
high identity-by-state, discordant sex or call rate <95%, 
and SNPs with call rate <95%, minor allele frequency 
<0.05 or deviation from the Hardy-Weinberg Equilibrium.
STATISTICAL ANALYSIS
SPSS software v25 (SPSS Inc., Chicago, Illinois) was used 
to perform the statistical analysis. Normality test 
(Kolmogorov-Smirnov) was performed to identify the 
normality of the variables. Odds ratio (OR) and the P-values 
for the investigated SNPs (P-values ≤0.05 were considered 
to be significant) were obtained using multiple regression. 
An OR >1.0 was deemed as the baseline risk whilst OR 
<1.0 as the baseline risk-lowering. An OR = 1 was 
considered as normal. Effective allele frequency (EAF) was 
calculated based on this formula: [(BB*2) + AB]/ 
[(AA+AB+BB)*2]. Unless otherwise stated, all data were 
presented as mean and standard deviation. The comparison 
between parameters among subjects was tested using 
independent t-test for normally distributed variables or 
Mann Whitney U test for skewed variables where 
appropriate. Count variables were compared using Chi 
square test.
ADDITIONAL VALIDATION OF GENOTYPE CALLS BY 
SEQUENCING
Validation was conducted by re-genotyping the significant 
SNP in a number of subjects, randomly selected from the 
samples using Sanger sequencing. A total of three cases 
and three controls genomic DNA representing each 
genotype group selected was cleaned up, optimized and 
sequenced.
RESULTS
A total of 90 tuberculosis patients were recruited for this 
study as shown in Table 1. Fifteen samples fall under the 
category of AT-DILI cases and 75 samples were controls 
made up of patients who were on anti-TB medication but 
did not develop AT-DILI. The patients with AT-DILI were 
predominantly Malays (56.6%), followed by Chinese 
(19.3%), Indians (14.5%), and others (9.6%). Out of the 
75 controls, 60% were Malays, 16% Chinese, 13.3% 
Indians, and 10.6% others. Pulmonary TB account for 
majority of the sample at 72.2%. Smear positive sputum 
was seen in 66.3% of the TB patients. There were no 
significant differences in gender (P = 0.924) and age 
between the two groups (P = 0.541), therefore, these 
variables were not taken into account for the subsequent 
adjustment. However, we did adjust for race despite the 
P-value is strongly suggesting no difference, partly because 
we think that the subjects were made up of multiple races.
We analysed the association of the SNPs in the anti-
tuberculosis drug metabolism pathway genes that include 
the well-studied NAT2, CYP2E1, SOD2, BACH1, and NOS2A 
(Huang 2014). Detailed information on the nine SNPs and 
their association results were obtained (Table 2). Frequency 
of effective alleles ranges from 0.10-0.80 in the overall 
subjects. The effective allele frequency was higher in the 
cases compared to the control for NAT2 rs4646267, 
NAT2*13 rs1041983, NAT2*6 rs1799930, and NOS2A 
rs11080344. Despite the difference in the frequency 
between the groups, statistical significant was not achieved 
in all SNPs except for NOS2A rs11080344. NOS2A 
rs11080344-C was associated with more than 2.7 fold risk 
of AT-DILI (adjusted OR 2.73, 95% CI 1.12-6.64, P = 
0.027). Nevertheless, we could not analyse the results by 
race stratification due to small sample size. We also 
extended our analysis for the remaining 161 SNPs within 
the selected chromosomes. However, there was no 
difference in allele frequency between the cases and 
controls (Supplementary Table 1).
DISCUSSION
In this study, we designed and genotyped 170 SNPs in our 
attempt to investigate the risk of AT-DILI. We paid special 
attention to nine SNPs involved in the anti-tuberculosis 
drug metabolism pathway genes and  previously reported 
to have a strong association with AT-DILI which include 
alleles of NAT2, CYP2E1, SOD2, NOS2A, and BACH1 (Huang 
2014). We found that NOS2A rs11080344 was significantly 
associated with AT-DILI in the Malaysian population with 
2.73 times greater risk of developing liver injury. 
One of the most widely studied genes that has been 
commonly linked to AT-DILI is NAT2. Polymorphisms of 
NAT2 gene has been seen to significantly affect functions 
by decreasing both enzyme stability and the rate of 
detoxification of drug metabolites in the liver. Allele variant 
of NAT2 can appear as either slow acetylator (two slow 
alleles), intermediate acetylator (1 slow and 1 rapid allele) 
or rapid acetylator (2 rapid alleles, sometimes referred to 
as ‘fast’) (McDonagh et al. 2014). Slow acetylators of NAT2 
variants are known to contribute to the development of 
AT-DILI (Wattanapokayakit et al. 2016). A clinical trial of 
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pharmacogenetics based therapy demonstrated that NAT2 
genotype guided administration of isoniazid considerably 
lowers DILI and early treatment failure in the intensive 
phase of the 6-month four-drug standard treatment of 
tuberculosis (Azuma et al. 2013). In this clinical trial, 
patients who are slow acetylators of NAT2 were given lower 
dosage of isoniazid as compared to the standard dosage, 
they showed no presence of DILI and demonstrated good 
clinical progress in tuberculosis (Azuma et al. 2013). A 
Taiwanese study showed that diplotype NAT2 6A/7B has 
nearly 8.8 times greater risk of AT-DILI, and similarly, a 
Brazilian study showed that slow acetylation of NAT2 
*6a/6 with 5.7 times greater risk of AT-DILI (Vizirianakis 
2014). A stratified analysis by ethnicity showed that slow 
acetylators of NAT2 and its susceptibility to anti-TB drug- 
induced hepatitis (ATDH) is significantly seen in the East 
Asian, South Asian, Brazilian and Middle Eastern 
populations but not the Caucasians (Du et al. 2013). In this 
study, however, we observed no significant association of 
NAT2*6A with AT-DILI. This result is in contrast with the 
Indonesian study (Yuliwulandari et al. 2016). Indonesia 
being a neighbouring country, is expected to share similar 
genetic structure with the Malaysian Malays. However, a 
phylogenetic tree in a study by Deng et al. (2015) showed 
a relatively different genetic makeup between the 
Peninsular Malays and Indonesian Malays. We also cannot 
rule out the admixture of ethnicity within our study 
population, despite the subjects were mainly Malays (Hatin 
et al. 2011).
We also failed to replicate a significant finding with 
polymorphism of CYP2E1 in our population. It has been 
reported that patients taking isoniazid while bearing the 
CYP2E1 C1/C1 genotype showed increased CYP2E1 
activity, hence more hepatotoxins as compared to the 
patients with other CYP2E1 genotype (Huang et al. 2003). 
A recent meta-analysis of 25 independent studies showed 
only six studies with homozygous CYP2E1 RsaI/PstI C1/
C1 polymorphism increases the risk of AT-DILI (Wang et 
al. 2016). This meta-analysis included studies done in the 
East Asian, Indian, South American, and Caucasian 
populations. According to the pooled estimate, the CYP2E1 
RsaI/PstI C1/C1 polymorphism is strongly associated with 
AT-DILI only in the East Asian population, and this 
observation is only agreed when ALT level is twice the 
ULN (Wang et al. 2016). However, when the criteria for 
cases is ALT >3× ULN, as being adopted by our study, 
CYP2E1 RsaI/PstI C1/C1 polymorphism showed no 
significant association (Wang et al. 2016). The meta-
analysis suggested that the association of CYP2E1 RsaI/
PstI C1/C1 polymorphism with AT-DILI is only seen in 
those with mild liver injury (Wang et al. 2016), thus, 
explains our conflicting result. 
SOD on the other hand, plays an important role against 
oxidative stress. SOD exist in three forms, namely 
cytoplasmic superoxide dismutase (SOD1), mitochondrial 
superoxide dismutase 2 (SOD2), and extracellular 
superoxide dismutase (SOD3). A polymorphism in 
manganese superoxide dismutase (MnSOD, SOD) from 
TABLE 1. Demographics and clinical profiles of the subjects
Severity n or mean ± SD P value
Case (n= 15) Control (n= 75)
Gender M:F 8:7 42:33 0.924
Race Malay 8 45 0.956
Chinese 4 12
Indian 1 1
Others 2 8
Type of TB Pulmonary 12 53 0.681
Ex-PTB 3 20
Both 0 2
Smear Smear +ve 12 45 0.240
Smear -ve 3 30
Age 42.1 (±17.5) 39.9 (±15.4) 0.541
Weight kg 46.8 (±6.63) 54.8 (±12.3) 0.059
After Total Bil (umol/L) 58.2 (±63.9) 9.4 (±4.8) <0.001
ALP (IU/L) 170.2 (±135.2) 94.2 (±32.2) 0.003
ALT (IU/L) 266.7 (±259.6) 37.6 (±34.5) <0.001
AST(IU/L) 215.3 (±142.8) 25.0 (±22.7) 0.019
150.0 (±146.4) 51.3 (±58.1) 0.003
Data are expressed as mean ± SD.
M, male; F, female; Ex-PTB, extrapulmonary; TB; Total Bil, Total Bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline 
phosphatase; GGT, gamma-glutamyl transferase; After, LFT level after drug exposure. 
P values were obtained by comparing cases and controls using independent t-test 
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thymine (T) to cytosine(C) demonstrated susceptibility to 
cancer and alcoholic liver disease (Huang 2014). Patients 
with variant C allele of reported MnSOD had a 2.47 times 
higher risk of developing AT-DILI (Huang 2014). Huang 
et al. (2007) and Lucena et al. (2010) found that SOD2 
polymorphism is associated with AT- DILI in the Taiwanese 
and Spanish, respectively. On the contrary, the  Korean 
cohort showed that the SOD2 polymorphism is not a risk 
(Kim et al. 2015). In the present study, our analysis supports 
the finding from the Korean cohort. 
Besides drug metabolizing enzymes, polymorphism 
in antioxidant enzyme or transcription factors such as nitric 
oxide synthase (NOS), is seen to link with AT-DILI (Huang 
2014). Toxic materials and free radicals are eliminated by 
the body with the help of antioxidant pathway proteins 
(Nanashima et al. 2012). Nitric oxide (produced by the 
inducible form of nitric oxide synthase; iNOS) produces 
peroxynitrite by reacting with superoxide anion radical 
02- (Nanashima et al. 2012). This in turns inactivates 
antioxidant enzymes by oxidizing thiols and methionine 
residue causing oxidative stress in hepatocytes (Nanashima 
et al. 2012). NOS2A rs11080344 C/C genotype influences 
the expression of NOS2A thus leading to gain-of –function 
of iNOS activity (Nanashima et al. 2012). NOS2A 
rs11080344 is located in the intron region and this 
polymorphism has the possibility to activate the enhancers 
and non-coding RNAs or inactivate the repressors that cause 
a gain of function of iNOS (Nanashima et al. 2012). 
Mutation in nitric oxide synthase 2A (NOS2A) (the inducible 
form of nitric oxide synthase; iNOS) produces more nitric 
oxide, thus, decreasing the function of antioxidant enzymes 
in the hepatocytes and causes anti-tuberculosis drug-
induced liver injury (AT-DILI) (Nanashima et al. 2012). To 
date, there is only one study from the Japanese investigating 
the association between NOS2A rs11080344 and AT-DILI 
and the authors showed that C/C genotype shows a high 
risk association with AT-DILI (Nanashima et al. 2012). We 
confirmed the NOS2A finding in our population. The 
association finding of NOS2A with AT-DILI in Malaysia 
suggests its further role in AT-DILI worth to be investigated. 
In the meantime, the same authors investigated the 
association between BACH1 rs2070401 and AT-DILI 
(Nanashima et al. 2012). Similarly, no significant finding 
was reported (Nanashima et al. 2012). Our result further 
confirmed the report. Interestingly, the effective allele 
frequency in our study is similar to the HapMap of the 
Japanese (0.06) (Zerbino et al. 2017). 
One main limitation of this study is the small sample 
size of AT-DILI patients. Samples were collected at only 
two hospitals, namely UMMC and IRM. IRM is the referral 
centre for respiratory diseases and majority of tuberculosis 
cases from Kuala Lumpur are treated here (Nissapatorn et 
al. 2007). These two were chosen, as compared to the other 
hospitals as they were actively involved in monitoring and 
reporting of AT-DILI cases. Despite low sample size, our 
study sample size is justifiable. In general, the sample size 
in pharmacogenetics of AT-DILI ranges from 18-185 for 
case subjects (Huang et al. 2007, 2002; Kim et al. 2015; 
Lucena et al. 2010; Nanashima et al. 2012; Teixeira et al. 
2011; Wattanapokayakit et al. 2016; Yuliwulandari et al. 
2016). Bigger sample size is often seen in a study adopted 
the ALT >2× ULN in defining the case subject (Huang et 
al. 2002; Lucena et al. 2010; Wattanapokayakit et al. 2016). 
It is noteworthy to mention that the study by Nanashima 
et al. (2012) on NOS2A had a sample size of 18 using the 
ALT >2× ULN criterion. Next, we did not investigate the 
association by racial breakdown as it will deem a low 
sample power. Although the incidence and mortality of TB 
in the country is relatively high (Ministry of Health 
Malaysia 2018) but there is still under reporting when it 
comes to AT-DILI cases in the country. 
CONCLUSION
Our study found a significant association of NOS2A and 
the risk of developing AT-DILI in Malaysia. We suggest 
that NOS2A genetic variant may play a role in disease 
modification. However, the scale of the NOS2A rs11080344 
effect warrants a future study in a bigger cohort which is 
always a dilemma in AT-DILI study. Perhaps, a regional 
collaboration is necessary to tackle this issue. We hope that 
these data provide information in the Malaysian setting 
with regards to genetic of AT-DILI to ensure a better 
monitoring of AT-DILI in the country.
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SUPPLEMENTARY 1. Analysis of other SNPs on chromosome 8, 10, 6,17, and 21
Chr Gene name SNP ID Alleles (Major/minor) P value OR(CI)
8 NA rs13277723 A/G 0.50 1.34 (0.58-3.14)
NA rs34546534 G/A 0.43 1.70 (0.46-6.30)
NAT2 rs7016785 A/G 0.34 0.68 (0.31-1.50)
NAT2 rs7013253 A/G 0.55 0.78 (0.36-1.72)
NAT2 rs10109286 A/G 1.00 1.00 (0.43-2.31)
NAT2 rs10095668 GG NIL NIL
NAT2 rs4921907 AA NIL NIL
NAT2 rs7825609 AA NIL NIL
NAT2 rs1565684 A/G 0.54 1.30 (0.56-3.02)
NAT2 rs4646241 A/G 0.33 0.67 (0.30-1.50)
NAT2 rs4646242 A/G 0.19 0.57 (0.25-1.31)
NAT2 rs4345600 A/G 1.00 1.00 (0.36-2.81)
NAT2 rs4351455 GG NIL NIL
NAT2 rs4271002 G/C 1.00 1.00 (0.36-2.81)
NAT2 rs4646246 A/G 0.46 1.40 (0.56-3.61)
NAT2 rs11780272 A/G 0.41 1.72 (0.48-6.16)
NAT2 rs13277605 A/C 0.41 1.72 (0.48-6.16)
NAT2 rs9987109 A/G 0.36 1.81 (0.50-6.54)
NAT2 rs2087852 A/G 0.19 0.57 (0.25-1.31)
NAT2 rs2410556 AA NIL NIL
NAT2 rs1390358 A/G 0.45 1.72 (0.48-6.16)
NAT2 rs11996129 A/G 0.69 1.17  (0.53-2.57)
NAT2 rs1115784 A/G 0.69 1.17 (0.53-2.57)
NAT2 rs1961456 A/G 0.79 1.12 (0.51-2.44)
NAT2 rs1112005 G/A 0.19 0.58 (0.26-1.3)
NAT2 rs973874 GG NIL NIL
NAT2 rs7832071 G/A 0.43 0.59 (0.16-2.20)
NAT2 rs1805158 GG NIL NIL
NAT2 rs1801279 GG NIL NIL
NAT2 rs1801280 A/G 0.41 1.72 (0.48-6.16)
NAT2 rs1799929 G/A 0.46 1.63 (0.46-5.80)
NAT2 rs4646247 G/A 0.14 1.88 (0.82-4.34)
NAT2 rs971473 G/A 0.80 0.86 (0.29-2.59)
NAT2 rs721398 A/G 0.19 1.74 (0.77-3.97)
NAT2 rs721399 G/A 0.52 1.29 (0.60-2.77)
NAT2 rs11784251 A/G 0.52 0.77 (0.36-1.67)
NAT2 rs4646248 G=A 0.44 1.35 (0.63-2.92)
NAT2 rs4646249 C=A 0.44 0.74 (0.34-1.60)
NAT2 rs4646250 G=A 0.44 1.35 (0.63-2.92)
NA rs10089306 GG NIL NIL
NA rs10088830 GG NIL NIL
NA rs1390360 A=G 0.44 1.35 (0.63-2.92)
NA rs1908586 A=G 0.93 1.05 (0.37-2.95)
NA rs2410557 CC NIL NIL
NA rs1908587 A/C 0.93 0.96 (0.35-2.62)
NA rs4455879 CC NIL NIL
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NA rs1495745 A=C 0.42 1.41 (0.61-3.25)
NA rs1495746 A/G 0.42 1.41 (0.61-3.25)
NA rs1495747 A=G 0.44 1.35 (0.53-2.92)
NA rs2410558 A/G 0.52 1.29 (0.60-2.77)
NA rs4540438 A/C 0.85 0.90 (0.30-2.70)
NA rs12674710 A/C 0.72 0.85 (0.35-2.04)
NA rs10103029 A/G 0.72 0.85  (0.35-2.04)
NA rs10088333 G/A 0.72 0.85 (0.35-2.04)
NA rs12543818 A/C 0.60 1.20 (0.56-2.70)
NA rs12545528 A/C 0.60 1.20 (0.56-2.70)
NA rs4921911 G/A 0.45 1.37 (0.61-3.06)
NA rs4921913 G/A 0.58 1.20 (0.55-3.00)
NA rs4921914 A/G 0.58 1.20 (0.55-3.00)
NA rs1495742 G/A 0.83 1.10 (0.46-2.53)
10 LOC107984284 rs9418988 G/A 0.13 0.53 (0.23-1.21)
LOC107984284 rs10857733 G/A 0.73 0.83 (0.29-2.4)
LOC107984284 rs10776687 G/A 0.73 0.83 (0.29-2.4)
LOC107984284 rs10857735 C/A 0.13 1.82 (0.84-3.95)
LOC107984285 rs10857736 A/G 0.13 1.82 (0.84-3.95)
CYP2E1 rs3813867 C/G 0.94 0.96 (0.38-2.46)
CYP2E1 rs2070673 T/A 0.11 1.9 (0.86-4.22)
CYP2E1 rs6413420 CC NIL NIL
CYP2E1 rs943975 G/A 0.73 1.21 (0.42-3.5)
CYP2E1 rs8192771 AA NIL NIL
CYP2E1 rs915906 A/G 0.04 0.40 (0.16-0.97)
CYP2E1 rs2070674 G/A 0.73 0.83 (0.28-2.4)
CYP2E1 rs2070675 G/A 0.16 1.74 (0.81-3.73)
CYP2E1 rs9919378 CC NIL NIL
CYP2E1 rs6413419 GG NIL NIL
CYP2E1 rs6413421 AA NIL NIL
CYP2E1 rs915907 C/A 0.14 1.77 (0.83-3.77)
CYP2E1 rs915908 G/A 0.67 0.78 (0.26-2.40)
CYP2E1 rs915909 GG NIL NIL
CYP2E1 rs8192775 G/A 0.82 1.11 (0.46-2.68)
CYP2E1 rs7092584 G/A 0.13 1.82 (0.84-3.95)
CYP2E1 rs743534 G/A 0.10 2.58 (0.83-8.07)
CYP2E1 rs743535 G/A 0.54 1.31 (0.55-3.10)
CYP2E1 rs11818144 AA NIL NIL
CYP2E1 rs1410897 G/A 0.08 2.78 (0.88-8.70)
CYP2E1 rs1329149 T/C 0.08 2.78 (0.88-8.70)
CYP2E1 rs2070676 G/C 0.08 2.78 (0.88-8.70)
CYP2E1 rs2070677 T/A 0.08 2.78 (0.88-8.70)
CYP2E1 rs2515641 G/A 0.16 1.75 (0.80-3.85)
CYP2E1 rs2515642 G/A 0.16 0.57 (0.26-1.26)
CYP2E1 rs2480259 A/G 0.18 0.58 (0.26-1.29)
CYP2E1 rs2480258 A/G 0.16 0.57 (0.26-1.26)
CYP2E1 rs2249694 A/G 0.15 0.57 (0.26-1.26)
CYP2E1 rs2249695 A/G 0.15 0.57 (0.26-1.26)
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CY2E1 rs9629960 CC NIL NIL
CYP2E1 rs12164704 AA NIL NIL
CYP2E1 rs12164799 GG NIL NIL
CYP2E1 rs2515644 A/C 0.12 0.54 (0.24-1.19)
NA rs1952467 A/G 0.16 0.57(0.26-1.26)
NA rs9629963 GG NIL NIL
NA rs9629923 AA NIL NIL
NA rs8192779 G/A 0.54 1.31 (0.55-3.10)
NA rs8192781 A/C 0.16 0.57 (0.26-1.26)
NA rs9629964 CC NIL NIL
NA rs12266332 AA NIL NIL
NA rs9629971 AA NIL NIL
NA rs12269057 AA NIL NIL
NA rs1536826 A/C 0.12 0.54 (0.24-1.19)
NA rs4512750 G/A 0.16 1.75 (0.80-3.85)
NA rs9629977 GG NIL NIL
NA rs11593189 A/G 0.30 1.58 (0.66-3.71)
6 NA rs2842985 G/A 0.56 1.27 (0.58-2.78)
NA rs9365085 G/A 0.94 1.03 (0.44-2.39)
NA rs732498 G/A 0.78 1.13 (0.49-2.61)
NA rs6911119 GG NIL NIL
NA rs4342445 G/A 0.94 1.03 (0.44-2.40)
SOD2 rs5746151 G/A 0.99 3.37E+08
NA rs6917589 A/G 0.94 1.03 (0.44-2.40)
SOD2 rs5746141 G/A 0.99 3.37E+08
SOD2 rs5746142 GG NIL NIL
SOD2 rs5746140 CC NIL NIL
SOD2 rs5746136 G/A 0.99 3.67 (0.0)
SOD2 rs5746135 G/A 1.00 3.28E+08
SOD2 rs2758331 A/C 0.72 0.86 (0.38-1.96)
SOD2 rs5746129 GG NIL NIL
SOD2 rs2855116 A/C 0.72 0.86 (0.38-1.96)
SOD2 rs4987023 GG NIL NIL
SOD2 rs6912979 A/G 0.69 0.85 (0.40-1.86)
SOD2 rs5746096 CC NIL NIL
SOD2 rs2758352 A/G 0.35 1.46 (0.67-3.20)
17 NOS2 rs12450521 C/A 0.88 0.94 (0.39-2.23)
NOS2 rs944722 A/G 0.18 0.51 (0.19-1.38)
NOS2 rs28944201 GG NIL NIL
NOS2 rs2297516 A/G 0.18 0.58 (0.26-1.30)
NOS2 rs28944173 A/G 0.99 3.32E+08
NOS2 rs2297518 G/A 1.00 1.00 (0.32-3.10)
NOS2 rs9797244 A/G 1.00 1.00 (0.32-3.10)
NOS2 rs3729720 GG NIL NIL
NOS2 rs3729718 AA NIL NIL
NOS2 rs4795067 A/G 0.20 0.51 (0.18-1.44)
NOS2 rs3729508 A/G 0.22 0.60 (0.27-1.35)
NOS2 rs944725 G/A 0.81 1.12 (0.45-2.77)
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NOS2 rs3730017 G/A 0.99 3.37E+08
NOS2 rs3794764 G/A 0.78 0.85 (0.27- 2.67)
NOS2 rs8072199 G/A 0.45 0.58 (0.14-2.38)
NOS2 rs16966563 G/A 0.99 3.37E+08
NOS2 rs3794766 G/A 0.78 0.85 (0.27-2.67)
21 LINC00189 rs733610 A/G 0.11 0.50  (0.21-1.20)
BACH1 rs1153284 A/C 0.20 0.42 (0.11-1.58)
BACH1 rs1153285 G/A 0.08 2.14 (0.90-5.09)
BACH1 rs2832283 G/A 0.13 0.21 (0.03-1.61)
BACH1 rs1236481 A/G 0.13 1.90 (0.83-4.34)
BACH1 rs7279721 G/A 0.17 0.27 (0.41- 1.78)
BACH1 rs1153284 A/G 0.20 2.38 (0.64-9.0)
BACH1 rs388707 A/G 0.47 0.75  (0.34-1.65)
BACH1 rs425989 G/A 0.47 0.75 (0.34-1.65)
BACH1 rs368322 C/T 0.10 3.6 (0.77-16.80)
BACH1 rs372883 A/G 0.30 0.66 (0.30-1.46)
BACH1 rs15092 G/A 0.10 3.60 (0.77-16.80)
BACH1 rs2027605 A/G 0.30 0.66 (0.30-1.46)
BACH1 rs4817283 A/G 0.67 0.82 (0.34-1.99)
Chr, Chromosome; NAT2, N-acetyltransferase 2; CYP2E1, cytochrome P450 2E1; SOD2, superoxide dismutase 2; NOS2A, nitric oxide synthase, 2A; BACH1, BTB domain 
and CNC homolog;
SNP ID, NCBI reference SNP (rs) number, an identification given by NCBI to SNPs
Odds Ratio (OR) and the P-values were determined using multiple logistic regression adjusted by race
